BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin C, Kizlik-Masson C, Pèlegrin A, Watier H, Viaud-Massuard MC, Joubert N. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France. MAbs 2018;10:210-21. [PMID: 29239690 DOI: 10.1080/19420862.2017.1412130] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Larivière M, Monteiro R. [The Antibody Club of the French Society of Immunology: structuring the assets of French research]. Med Sci (Paris) 2019;35:1206-7. [PMID: 31903942 DOI: 10.1051/medsci/2019221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Abdollahpour-Alitappeh M, Lotfinia M, Bagheri N, Sineh Sepehr K, Habibi-Anbouhi M, Kobarfard F, Balalaie S, Foroumadi A, Abbaszadeh-Goudarzi G, Abbaszadeh-Goudarzi K, Abolhassani M. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. J Cell Physiol 2019;234:2693-704. [PMID: 30246298 DOI: 10.1002/jcp.27085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
3 Park MH, Lee BI, Byeon JJ, Shin SH, Choi J, Park Y, Shin YG. Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Molecules 2019;24:E2754. [PMID: 31362431 DOI: 10.3390/molecules24152754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Vance N, Zacharias N, Ultsch M, Li G, Fourie A, Liu P, Lafrance-vanasse J, Ernst JA, Sandoval W, Kozak KR, Phillips G, Wang W, Sadowsky J. Development, Optimization, and Structural Characterization of an Efficient Peptide-Based Photoaffinity Cross-Linking Reaction for Generation of Homogeneous Conjugates from Wild-Type Antibodies. Bioconjugate Chem 2019;30:148-60. [DOI: 10.1021/acs.bioconjchem.8b00809] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
5 Aubrey N, Allard-vannier E, Martin C, Bryden F, Letast S, Colas C, Lakhrif Z, Collinet N, Dimier-poisson I, Chourpa I, Viaud-massuard M, Joubert N. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro. Bioconjugate Chem 2018;29:3516-21. [DOI: 10.1021/acs.bioconjchem.8b00668] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
6 Fang Y, Lin D, Yao S. Tetrapeptide ligands screening for antibody separation and purification by molecular simulation and experimental verification. Biochemical Engineering Journal 2021;176:108213. [DOI: 10.1016/j.bej.2021.108213] [Reference Citation Analysis]
7 Bonnet M, Maisonial-Besset A, Zhu Y, Witkowski T, Roche G, Boucheix C, Greco C, Degoul F. Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029. Cancers (Basel) 2019;11:E179. [PMID: 30769765 DOI: 10.3390/cancers11020179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
8 Chen T, Liu X, Hong H, Wei H. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect. J Transl Med 2020;18:376. [PMID: 33023595 DOI: 10.1186/s12967-020-02538-y] [Reference Citation Analysis]
9 Larivière M, Pèlegrin A, Martineau P, Watier H. [Players from the program "Investments for the Future": MAbImprove MabEx]. Med Sci (Paris) 2019;35:1204-5. [PMID: 31903941 DOI: 10.1051/medsci/2019249] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Hasan M, Leak RK, Stratford RE, Zlotos DP, Witt-Enderby PA. Drug conjugates-an emerging approach to treat breast cancer. Pharmacol Res Perspect 2018;6:e00417. [PMID: 29983986 DOI: 10.1002/prp2.417] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
11 Lee BI, Park MH, Choi J, Shin SH, Byeon JJ, Park Y, Shin YG. Liquid chromatography-high resolution mass spectrometric method for the quantification of monomethyl auristatin E (MMAE) and its preclinical pharmacokinetics. Biomed Chromatogr 2020;34:e4855. [PMID: 32304111 DOI: 10.1002/bmc.4855] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Elter A, Yanakieva D, Fiebig D, Hallstein K, Becker S, Betz U, Kolmar H. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity. Front Immunol 2021;12:715719. [PMID: 34413859 DOI: 10.3389/fimmu.2021.715719] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Esnault C, Leblond V, Martin C, Desgranges A, Baltus CB, Aubrey N, Lakhrif Z, Lajoie L, Lantier L, Clémenceau B, Sarma B, Schrama J, Houben R, Schrama D, Hesbacher S, Gouilleux-Gruart V, Feng Y, Dimitrov D, Guyétant S, Berthon P, Viaud-Massuard MC, Samimi M, Touzé A, Kervarrec T. Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. Br J Dermatol 2021. [PMID: 34582565 DOI: 10.1111/bjd.20770] [Reference Citation Analysis]
14 Beck A, D’atri V, Ehkirch A, Fekete S, Hernandez-alba O, Gahoual R, Leize-wagner E, François Y, Guillarme D, Cianférani S. Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future. Expert Review of Proteomics 2019;16:337-62. [DOI: 10.1080/14789450.2019.1578215] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
15 Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel) 2020;13:E245. [PMID: 32937862 DOI: 10.3390/ph13090245] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
16 Beck A, Dumontet C, Joubert N. [Antibody-drug conjugates in oncology. Recent success of an ancient concept]. Med Sci (Paris) 2019;35:1034-42. [PMID: 31903915 DOI: 10.1051/medsci/2019227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lee BI, Park MH, Byeon JJ, Shin SH, Choi J, Park Y, Park YH, Chae J, Shin YG. Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate. Molecules 2020;25:E1515. [PMID: 32225092 DOI: 10.3390/molecules25071515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
18 Fu Y, Ho M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antib Ther 2018;1:33-43. [PMID: 30294716 DOI: 10.1093/abt/tby007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]